6505--Acamprosate CA EC Tablets
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), specifically the NAC PHARMACEUTICALS (36E797) office, is soliciting proposals for Acamprosate Calcium (CA) 333MG Enteric Coated (EC) Tablets. This unrestricted procurement aims to establish a national contract for the supply of these tablets to the VA, Department of Defense (DoD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The contract will be a Firm Fixed Price, Indefinite-Delivery Requirements type, with one base year and four one-year option periods. Proposals are due May 28, 2026, at 2:30 PM CDT.
Scope of Work
The requirement is for Acamprosate Calcium (CA) 333MG Tablets, EC, 180 Tablets per Bottle (Unit of Use). Key product specifications include:
- Packaging: Unit of use bottles with a safety cap, minimum 120cc volume, cylindrical body with a minimum 5.75” circumference, and space to fit a 5.25” x 2” label with an additional 0.5” for barcode/expiration/lot number.
- National Drug Code (NDC): Offerors must provide a unique 11-digit NDC for each product.
- Quality & Compliance: Manufacturing facilities must have acceptable cGMP status with the FDA. Products must include GS1-128 or HIBCC compliant bar code labeling and comply with the Drug Supply Chain Security Act (DSCSA).
- Distribution: Products will be distributed through the Government Pharmaceutical Prime Vendor (PPV) Programs for VA and DoD. Estimated annual usage is 33,661 bottles of 180-count tablets.
Contract & Timeline
- Contract Type: Firm Fixed Price, Indefinite-Delivery Requirements.
- Period of Performance: One base year plus four one-year option periods.
- Set-Aside: Unrestricted.
- Offer Due Date: May 28, 2026, at 2:30 PM CDT.
- Published Date: May 14, 2026.
Submission & Evaluation
- Submission Method: Proposals must be submitted electronically via email to Deborah.Fassl@va.gov and Nicholas.McGregor@va.gov. Submissions should be in Microsoft Word or PDF format and include a scanned PDF of the signed SF-1449. Faxed proposals are not accepted.
- Pricing: Offerors must submit prices for the base year and all four option years, ensuring prices do not exceed two decimal places and include a 0.5% Cost Recovery Fee.
- Evaluation Criteria: Award will be made to the responsible offeror with the lowest price technically acceptable (LPTA) offer. Technical acceptability requires meeting product descriptions, having a unique NDC, FDA approval, FDA cGMP compliance, and manufacturing facility clearance.
Eligibility
- This acquisition is unrestricted.
- Offerors must maintain current and accurate registration in the System for Award Management (SAM).
- If the offeror is not the manufacturer, a Letter of Commitment from the manufacturer is required.
Additional Notes
The solicitation incorporates various FAR clauses by reference, including FAR 52.212-1, 52.212-4, and 52.212-5. Attachment D provides a template for Small Business Subcontracting Plans, which are required for other than small business concerns on contracts exceeding $900,000. The NAICS code for this opportunity is 325412.